It was learned from the Dongying City Agricultural Institute in Shandong Province that the animal mammary gland bioreactor, which was listed in the National 863 Program for transgenic animals, has achieved important results in recent days. The GM rabbit produced by the research group was born one after another in a local farm from January to February in 2004. According to the latest test, among the 184 new born rabbits, 89 were positive individuals, and the positive rate reached 48.4%. Both the transgenic efficiency and the number of transgenic animals achieved major breakthroughs. This research was hosted by Deng Jixian, a researcher of the Chinese Academy of Military Medical Sciences, and related personnel from related scientific research and production units such as Shandong Laiyang Agricultural College and Dongying Tianyi Biotech Co., Ltd. jointly participated in the study. Animal mammary gland bioreactors are large-scale production of pharmaceutical proteins or other biologically active substances for the treatment and care of human diseases by preparing transgenic animals and using their mammary glands. Mammary glands of transgenic animals can replace bacteria and cells and other organisms for fermentation, and can effectively post-process and modify the produced protein. Therefore, animal mammary gland bioreactors are recognized internationally as one of the most promising directions in the research of transgenic animals, and are also an important way to realize the enticing prospects of genetic engineering pharmaceuticals.